invest summari reiter neutral rate lower
pt highlight quick take think
quarter beat guidanc line investor expect think
investor like knew low-end guidanc would probabl outsid
consensu also think wide rang guidanc well-
telegraph compani think stock base
guidanc updat
appreci move piec like neulasta sensipar
think could upsid low end view think amgen
track record provid conserv guidanc especi relat low
end rang model top-lin revenu vs guidanc
bottom-lin vs guidanc
think enbrel revenu like remain fairli stabl vs trend estim
vs model yoy eros neulasta sensipar
think aimovig parsabiv repatha biosimilar could point upsid
guidanc current launch migrain aimovig
major share far volum increas repatha encourag though
next quarter net price decreas off-set volum long-term think
volum like drive growth degre think parsabiv
function happen sensipar market think less competit
gener would favor parsabiv
pipelin look robust awhil led mani proof concept readout
oncolog focus sinc think sound
quit bullish kra program also interest
glioblastoma target egfrviii compani drawn attent
program multipl myeloma lymphoma
data well remain uncertain whether see xmab program
licens ow excit bi-
specif platform model credit oncolog asset base case
sale
last least compani cash reserv signific
think sound construct certain valuat
would expect would like key therapeut
area like cardio oncolog mayb neurolog
disclosur section may found page
use probability-adjust dcf analysi valu share assum discount rate
model revenu assum termin valu roughli
valuat base termin valu reflect compani intern
engin pipelin program yet model
risk price target neutral rate includ greater-than-expect eros
base busi challeng earn project payer price challeng new
current product late-stag pipelin setback unexpect earli success pipelin asset
sever largest product biosimilar threat emerg come quarter
compani oper payer sensit market particularli cardiovascular diseas
repatha compani also robust early-stag pipelin given credit
either signific upsid downsid to/from program remain risk rate
price target
sale non-gaap
product sale
sale non- ex-royalti
product sale
aimovig royalti payment nv
biosimilar royalti payment agn
tezepelumab royalti payment azn
research develop non-gaap
total revenu
sell gener administr
total revenu
interest incom net exclud interest expens net non-gaap
interest incom expens net non-gaap
incom incom tax non-gaap
provis benefit incom tax non-gaap
adjust oper expens
incom incom tax
non- reconcili
sale gaap
certain net charg pursuant restructur initi
sale non-gaap
research develop
certain net charg pursuant restructur initi
research develop non-gaap
sell gener administr gaap
certain net charg pursuant restructur initi
sell gener administr non-gaap
interest incom net exclud interest expens net
adjust incom
interest incom net exclud interest expens net non-gaap
interest incom expens net
provis benefit incom tax gaap
incom tax effect adjust
provis benefit incom tax non-gaap
chang wc
present valu
npv
npv tv
tv total
total sale
diversifi biopharmaceut compani special six therapeut area includ cardiovascular diseas oncolog
bone health neurosci nephrolog inflamm compani also grow biosimilar franchis
